Novavax said on Wednesday the U.S. Food and Drug Administration had asked the company to produce more data on its COVID-19 ...

Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug ...

Novavax on Wednesday said the U.S. Food and Drug Administration has asked the company to commit to produce more data on its ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

Novavax's vaccine has been available since 2022 in the U.S. after the FDA granted its emergency use. "We look forward to ...

Investing.com -- Novavax (NASDAQ: NVAX) shares surged 13% following the biotechnology company’s optimism about its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA).

The FDA has asked Novavax to commit to producing post-marketing data of its Covid vaccine, the clearest example yet that the bar is higher for advancing new vaccines under HHS Secretary Robert F.

Novavax (NVAX) stock surges after the US Food and Drug Administration (FDA) requested COVID vaccine data from the company, which could signal that FDA approval is incoming.

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, declaring that single antigen ...

In the wake of unprecedented workforce cuts at the FDA, former Commissioner Scott Gottlieb and an unnamed former CBER ...

One of the FDA’s recently departed top officials is weighing in on the wide-ranging staff cuts at the agency and how they ...